# Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

> **NCT04456673** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 935 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Dupilumab SAR231893
- **DRUG:** Inhaled Corticosteroid
- **DRUG:** Inhaled Long-Acting Beta Agonist
- **DRUG:** Inhaled Long-Acting Muscarinic Antagonist
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04456673
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-05-27
- **Target enrollment:** 935 (ACTUAL)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456673, "Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT04456673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*